Literature DB >> 28865329

A retrospective clinicopathological study of lung adenocarcinoma: Total tumor size can predict subtypes and lymph node involvement.

Cheng Chen1, Zhijun Chen1, Hanbo Cao2, Jinggang Yan2, Zhaoyu Wang3, Hanbo Le1, Jingjing Weng1, Yongkui Zhang4.   

Abstract

PURPOSE: To analyze the predictive ability of total tumor size in lung adenocarcinoma subtype and lymph node involvement.
MATERIALS AND METHODS: 1018 patients, ≤3cm tumor, were enrolled. The maximum diameter and other variables of each tumor were measured.
RESULTS: The optimal cut-off value for total tumor size in differentiating AIS and MIA from IAC was <1.15cm, in distinguishing lymph node involvement, it was 1.65cm.
CONCLUSIONS: Total tumor size could be a reliable predictor of lung adenocarcinoma subtype and lymph node involvement irrespective of ground glass, part solid and solid characteristics.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adenocarcinoma in situ; Invasive adenocarcinoma; Lymph node involvement; Minimally invasive adenocarcinoma; Total tumor size

Mesh:

Year:  2017        PMID: 28865329     DOI: 10.1016/j.clinimag.2017.08.009

Source DB:  PubMed          Journal:  Clin Imaging        ISSN: 0899-7071            Impact factor:   1.605


  3 in total

1.  Surgery for mediastinal lymph node and early stage lung cancer: individualized practice based on clinical database.

Authors:  Yi-Ting Yen; Yau-Lin Tseng
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

2.  Different distant metastasis patterns based on tumor size could be found in extensive-stage small cell lung cancer patients: a large, population-based SEER study.

Authors:  Jia Li; Feng Liu; Haining Yu; Chenglong Zhao; Zhenxiang Li; Haiyong Wang
Journal:  PeerJ       Date:  2019-12-03       Impact factor: 2.984

3.  Usefulness of Hybrid PET/MRI in Clinical Evaluation of Head and Neck Cancer Patients.

Authors:  Natalia Samolyk-Kogaczewska; Ewa Sierko; Dorota Dziemianczyk-Pakiela; Klaudia Beata Nowaszewska; Malgorzata Lukasik; Joanna Reszec
Journal:  Cancers (Basel)       Date:  2020-02-22       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.